What ACS Dobfar does

ACS Dobfar (legal entity ACS DOBFAR S.p.A.) is a privately held Italian chemical-pharmaceutical company founded in 1973, headquartered in Tribiano (Milan) with an administrative office in Agrate Brianza. The company operates as a fully integrated anti-infective pharmaceutical manufacturer and CDMO/CMO, producing Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs) across three core therapeutic classes: Cephalosporins, Carbapenems, and Penicillins. Manufacturing capabilities span chemical synthesis (lab through industrial scale), microbial fermentation and downstream purification, sterile bulk processing (crystallisation, lyophilisation, dry powder filling), biocatalysis, and enzyme immobilisation. The company operates 11 Italian production sites and, through wholly-owned subsidiaries in Brazil (Antibioticos do Brasil, BEKER), Romania (Infomed Fluids), Switzerland (Inforlife), and Tunisia (Infomed Pharma), extends to a total of 20 production facilities and 7 distribution centres across four continents serving over 100 countries with more than 3,500 employees.

The company's revenue model combines custom development and manufacturing (CDMO/CMO) services for pharmaceutical innovators and multinationals with own-brand API and FDF sales. Proprietary differentiated offerings include STERBAG, a patented multi-layer sterile API packaging system, and SMARTPAK, a drug delivery and packaging system designed for hospital pharmacy compounding centers. The company holds multi-jurisdiction regulatory approvals (AIFA, FDA, ANVISA, MFDS), maintains ISO 14001:2015 and UNI ISO 45001:2023 certifications, and runs an E&L laboratory accredited by FDA, AIFA, and ANVISA. Forward-looking capability investments include a planned 200-litre bioreactor facility for monoclonal antibody CDMO services targeted for 2028, a biocatalysis and enzyme immobilisation platform, and emerging biotech services covering heterologous protein production, plasmid DNA, and liposome formulation.

ACS Dobfar serves two primary customer segments: enterprise pharmaceutical companies requiring custom API/FDF development and commercial manufacturing, and hospital pharmacy compounding centers purchasing the SMARTPAK system for sterile antibiotic reconstitution. Go-to-market is exclusively B2B via direct sales teams and regional subsidiaries. Pricing is quote-based and negotiated per engagement; no public pricing disclosure exists. Sustainability commitments include a Net Zero target by 2050 with SBTi submission planned for H1 2026, and the company was awarded EcoVadis Bronze Medal in April 2025. The company is family-owned and has not disclosed external funding rounds or ownership transactions.

Name

ACS Dobfar

Legal name

ACS DOBFAR S.p.A.

Website

https://acsdobfar.it

Company type

Private

Founded year

1973

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

ACS Dobfar is a privately held Italian CDMO and API/FDF manufacturer founded in 1973, specialising in anti-infective pharmaceuticals (cephalosporins, carbapenems, penicillins) with 20 production facilities across four continents serving pharmaceutical innovators and hospital pharmacies in over 100 countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical API & CDMO Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

Keywords

• Active pharmaceutical ingredients
• Contract drug manufacturing
• Sterile antibiotic manufacturing
• Finished dosage forms
• Biopharmaceutical CDMO services

Headquarters

HQ city

Agrate Brianza

HQ country

Italy

HQ region

Europe

Offices16 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Custom Development and Manufacturing (CDMO/CMO) Services: ACS Dobfar provides custom development and custom manufacturing services to pharmaceutical innovators and multinational companies. Services include process development, analytical method development, scale-up, and commercial manufacturing for both Drug Substances (APIs) and Drug Products (Finished Dosage Forms). This is the primary revenue driver as a CDMO.
2. Active Pharmaceutical Ingredients (APIs) Sales: Manufacturing and sale of own-brand and custom APIs including Cephalosporins, Penicillins, Carbapenems, and other anti-infective APIs. Products include sterile and non-sterile forms sold to pharmaceutical companies globally.
3. Finished Dosage Forms (FDFs) Sales: Manufacturing and sale of finished dosage forms including oral products (capsules, tablets, oral suspensions) and injectable products (vials, infusion bags, minibags) for cephalosporins, penicillins, and carbapenems.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

ACS Dobfar is a B2B CDMO/CMO that develops, manufactures, and supplies anti-infective Active Pharmaceutical Ingredients (cephalosporins, carbapenems, penicillins) and Finished Dosage Forms (oral capsules/tablets/suspensions and injectable vials, infusion bags, and minibags) to pharmaceutical companies globally. The company also provides custom process development, analytical method development, scale-up, and commercial manufacturing services, backed by proprietary STERBAG and SMARTPAK packaging systems and biotech capabilities covering enzyme immobilisation, microbial fermentation, and monoclonal antibody development.

Product overview

ACS Dobfar operates as a fully integrated pharmaceutical manufacturer offering a comprehensive portfolio spanning Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDFs), and advanced packaging solutions. The core product lines include Cephalosporin, Carbapenem, and Penicillin APIs manufactured at Italian facilities, complemented by oral and injectable finished dosage forms. Key branded offerings include STERBAG® (patented sterile API packaging) and SMARTPAK® (drug delivery system for hospital compounding). The company provides CDMO services through its Custom Development & Manufacturing division, Biotech services for enzyme and protein work, and Monoclonal Antibodies platform development. With over 50 years of experience since founding in 1973, ACS Dobfar serves over 100 countries worldwide through approximately 20 production facilities employing over 3,500 people.

Differentiator

Problem solved

Functional benefit

Brands

• STERBAG: A patented, high-performance packaging system designed for Sterile APIs, featuring multi-layer protection with vacuum-sealed polyethylene bags and aluminum layers.
• SMARTPAK

Products and services

• Active Pharmaceutical Ingredients (APIs) Fully integrated manufacturer of Cephalosporin, Carbapenem, and Penicillin APIs (sterile and non-sterile forms) including Cefazolin, Ceftriaxone, Meropenem, Ampicillin, and Ertapenem, sold to global pharmaceutical customers.
• Finished Dosage Forms (FDFs) Oral and injectable finished dosage forms including Cephalexin, Cefaclor, Cefixime capsules and suspensions, and injectable antibiotics (Cefazolin, Ceftriaxone, Ampicillin, Meropenem) in various vial sizes for global pharmaceutical customers.
• STERBAG Packaging System Patented multi-layer packaging system for sterile APIs using vacuum-sealed polyethylene bags (LDPE and HDPE) with an aluminum outer layer, protecting products from light, moisture, and external factors during storage and transportation.
• SMARTPAK Drug Delivery & Packaging System Innovative drug delivery and packaging system designed to streamline and enhance reconstitution of antibiotics within Hospital Pharmacy Compounding Centers, reducing handling steps, contamination risks, and preparation complexity for sterile cephalosporins.
• Custom Development & Manufacturing Services (CDMO/CMO) CDMO services providing custom commercial manufacturing and packaging, process development, analytical method development, scale-up, and regulatory support for pharmaceutical innovators and multinational companies across anti-infective APIs and finished dosage forms.
• Biotech Services R&D services including enzyme purification and immobilisation, heterologous proteins production, microbial biomasses cultivation, plasmid DNA production, and liposome formulation for therapeutic applications.
• Monoclonal Antibodies (mAbs) Development Platform State-of-the-art development platform dedicated to monoclonal antibodies for CDMO services, supporting Phase 1 and Phase 2 clinical programs via a planned 200-litre bioreactor facility.
• RTU Infusion Bags / Minibags Ready-to-use infusion bags containing pre-formulated injectable antibiotics including Cefazolin, Cefuroxime, Cefepime, Ceftriaxone, Piperacillin-Tazobactam, and Vancomycin in various sizes.
• In Use Stability Studies Stability testing services demonstrating drug product performance under in-use conditions, testing various diluents (NaCl 0.9%, Dextrose 5%, Ringer, etc.) at different temperatures and storage conditions.
• Extractable & Leachable Testing E&L laboratory services for identification and quantitation of extractables, leachables, mutagenic impurities, nitrosamines, and elemental impurities using HS-GC/MS, GC/MS, LC/MS, and ICP/MS instrumentation, supporting ICHQ3D, ICHM7 compliance and ICHQ3E readiness.

Quantifiable outcome

• ACS Dobfar was awarded Bronze Medal in April 2025, ranking among top 35% of companies assessed globally for sustainability.
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• EUROAPI: French API and CDMO spun off from Sanofi, one of the largest Western API manufacturers with broad small-molecule portfolio. Comparable in API manufacturing scale, CDMO positioning, and regulatory footprint to ACS Dobfar.
• Siegfried Holding: Swiss-listed CDMO offering API and finished dose manufacturing including sterile filling. Comparable in integrated CDMO model, multi-site European footprint, and customer base of innovator pharmaceutical companies.
• Hovione: Portuguese CDMO specializing in API development, particle engineering, and aseptic fill-finish. Comparable as a privately held, science-driven CDMO with integrated API-to-drug-product capabilities.
• FAREVA: French private CDMO with sterile injectable and API capabilities, serving global pharmaceutical clients. Similar end-to-end CDMO positioning, regulatory depth, and European manufacturing footprint.
• Aenova Holding: German CDMO with broad solid, semi-solid, and sterile manufacturing capabilities for pharma innovators. Comparable scale and integrated CDMO offering serving multinational pharmaceutical customers.
• Recipharm: Swedish-headquartered CDMO with extensive sterile injectable and API capabilities across Europe. Comparable integrated CDMO positioning and breadth of pharmaceutical manufacturing services.
• Centrient Pharmaceuticals: Dutch-headquartered manufacturer of β-lactam antibiotics (cephalosporins, penicillins) and statins via enzymatic and fermentation processes. Direct overlap with ACS Dobfar's anti-infective API focus and similar CDMO/API business model.
• Curia Global: US-headquartered CDMO providing API development, sterile fill-finish, and commercial manufacturing. Comparable end-to-end CDMO service portfolio and exposure to innovator pharma outsourcing.
• Olon SpA: Italian-headquartered API and CDMO with a strong focus on generics and fermentation-derived APIs, including anti-infectives. Comparable in size, geography, and fermentation/small-molecule manufacturing model to ACS Dobfar's core API business.

Emerging players

• AGC Biologics (AGC Inc.): Global CDMO focused on mammalian cell-based biologics, mAb manufacturing, and cell/gene therapy. Relevant as the type of biologics-focused competitor ACS Dobfar is targeting with its planned 200-litre mAb bioreactor facility.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ACS Dobfar